Neu­vo­gen un­cloaks with broad plan of at­tack for whole-cell can­cer vac­cines, clin­i­cal hopes with­in the year

Af­ter about four stealthy years in the de­vel­op­ment phase, San Diego-based Neu­vo­gen is emerg­ing with a new ap­proach to whole-cell can­cer vac­cines and nine sol­id tu­mor pro­grams bound for the clin­ic.

Whole-cell tu­mor vac­cines are de­vel­oped by tak­ing can­cer cells from pa­tients and mod­i­fy­ing them to make them im­muno­genic.

“What’s dif­fer­ent from what we do, is most peo­ple use one cell line. We use six,” CEO Todd Binder said. From there, the com­pa­ny builds out six mod­i­fi­ca­tions to elim­i­nate prob­lem­at­ic im­muno­sup­pres­sive fac­tors, and add what the ex­ec­u­tive called three “stim­u­la­to­ry fac­tors” to gen­er­ate a prime and over­come pe­riph­er­al tol­er­ance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER